Citations

Showing 10 of 108104 citations.

Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment
Cerhan, Leah P., Roberts, Rosebud O., Mielke, Michelle M. , Syrjanen, Jeremy A. , Christianson, Teresa J., Petersen, Ronald C. , Geda, Yonas E. , Mielke, Michelle M , Geda, Yonas E , Krell‐Roesch, Janina , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Alzheimer Disease & Associated Disorders | August 14, 2018 | Volume: 33 | Issue: 1 | Pages: 68-71

10.1097/wad.0000000000000266 | PMID 30106755 Get It

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer
Rounbehler, Robert J., Berglund, Anders , Gerke, Travis , Takhar, Mandeep, Awasthi, Shivanshu , Li, Weimin , Davicioni, Elai , Erho, Nicholas , Ross, Ashley E. , Schaeffer, Edward M. , Klein, Eric A. , Karnes, R. Jeffrey , Jenkins, Robert B. , Yamoah, Kosj , Davicioni, Elai , Klein, Eric A , Berglund, Anders E , Cleveland, John L. , Park, Jong Y.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 14, 2018 | Volume: 27 | Issue: 11 | Pages: 1376-1383

10.1158/1055-9965.epi-18-0369 | PMID 30108099 Get It

AbstractBackground: We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP).Methods: TTP RNA expression was measured in an RP cohort of patients treated at Moffitt Cancer Center (MCC) and obtained from six publically available RP datasets with biochemical recurrence (BCR; total n = 1,394) and/or metastatic outcome data (total n = 1,222). TTP protein expression was measured by immunohistochemistry in a tissue microarray of 153 MCC RP samples. The time to BCR or metastasis based on TTP RNA or protein levels was calculated using the Kaplan–Meier analysis. Univariable and multivariable Cox proportional hazard models were performed on multiple cohorts to evaluate if TTP is a clinically relevant biomarker and to assess if TTP improves upon the Cancer of the Prostate Risk Assessment postsurgical (CAPRA-S) score for predicting clinical outcomes.Results: In all of the RP patient cohorts, prostate cancer with low TTP RNA or protein levels had decreased time to BCR or metastasis versus TTP-high tumors. Further, the decreased time to BCR in TTP-low prostate cancer was more pronounced in low-grade tumors. Finally, pooled survival analysis suggests that TTP RNA expression provides independent information beyond CAPRA-S to predict BCR.Conclusions: TTP is a promising prostate cancer biomarker for predicting which RP patients will have poor outcomes, especially for low-grade prostate cancer patients.Impact: This study suggests that TTP RNA expression can be used to enhance the accuracy of CAPRA-S to predict outcomes in patients treated with RP. Cancer Epidemiol Biomarkers Prev; 27(11); 1376–83. ©2018 AACR.
A Case Series of Parechovirus Encephalopathy: Apnea and Autonomic Dysregulation in Critically Ill Infants
Ristagno, Elizabeth H. , Bhalla, Sonam , Rasmussen, Lindsey

Mayo Clinic

Journal of Child Neurology | August 14, 2018 | Volume: 33 | Issue: 12 | Pages: 788-793

10.1177/0883073818789317 | PMID 30105932 Get It

This article aims to describe a rare cause of severe encephalitis in 2 cases of infants with signs of intracranial hypertension and severe autonomic dysregulation. The authors conclude that human parechoviruses are becoming a more recognized cause of encephalitis because of the increasing use of rapid detection methods. With early recognition of this clinical entity, improved care can be administered.
Mimicking Human Pathophysiology in Organ‐on‐Chip Devices
Hassan, Shabir , Miri, Amir K. , Maharjan, Sushila , Al‐kharboosh, Rawan , Quiñones‐Hinojosa, Alfredo , Zhang, Yu Shrike , Zhang, Yu Shrike , Yeşil-Çeliktaş, Özlem , Maharjan, Sushila

Mayo Clinic

Advanced Biosystems | August 14, 2018 | Volume: 2 | Issue: 10 | Pages: No page available

10.1002/adbi.201800109 Get It

AbstractConvergence of life sciences, engineering, and basic sciences has opened new horizons for biologically inspired innovations, and a considerable number of organ‐on‐a‐chip platforms have been developed for mimicking physiological systems of biological organs such as the brain, heart, lung, kidney, liver, and gut. Various biophysicochemical factors can also be introduced into such organ‐on‐a‐chip platforms to study metabolic and systemic effects spanning from drug toxicity to different pathologic manifestations. There is also a pressing need to develop better disease models for common pathologies using variations of these platforms. This can be achieved by recapitulating the unique microenvironment of a disease to investigate the cause and development of abnormal conditions as well as the structural and functional changes resulting from such a pathology. In this review, the organ‐on‐a‐chip platforms that have been developed to model different pathologies of neurodegenerative, cardiovascular, respiratory, hepatic, and digestive systems, along with cancer are summarized. Although the field is still in its infancy, it is anticipated that developing disease model‐on‐a‐chip platforms will likely be a valuable addition to the field of disease modeling, pathology studies, and improved drug discovery.
Increased Iris Stiffness in Patients With a History of Angle-Closure Glaucoma: An Image-Based Inverse Modeling Analysis
Pant, Anup , Gogte, Priyanka, Pathak-Ray, Vanita , Dorairaj, Syril , Dorairaj, Syril K., Amini, Rouzbeh

Mayo Clinic

Investigative Opthalmology & Visual Science | August 14, 2018 | Volume: 59 | Issue: 10 | Pages: 4134

10.1167/iovs.18-24327 | PMID 30105368 Get It

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty‐nine patients
Pophali, Prateek , Finke, Christy M. , Gangat, Naseema , Nagorney, David M. , Tefferi, Ayalew , Patnaik, Mrinal M. , Horna, Pedro , Lasho, Terra L. , Gangat, Naseema , Nagorney, David, Tefferi, Ayalew , Patnaik, Mrinal , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | August 14, 2018 | Volume: 93 | Issue: 11 | Pages: 1347-1357

10.1002/ajh.25246 | PMID 30105755 Get It

AbstractIn a 28‐year period, 39 (7%) patients with chronic myelomonocytic leukemia (CMML) (median age 66 years, 64% male) underwent a splenectomy at our institution. Primary indications for splenectomy were refractory thrombocytopenia (36%), progressive spleen related symptoms (33%), emergent splenectomy for splenic rupture (21%), refractory anemia (8%), and prior to allogeneic stem cell transplant (3%). Eleven (28%) patients had anemia at the time of splenectomy, of which 3 (27%) were autoimmune. The median time to splenectomy from CMML diagnosis was 6 months (0‐40); perioperative morbidity and mortality rates were 43% and 13%, while the median postsplenectomy survival was 25 months (11‐38). Durable remission in spleen related symptoms, thrombocytopenia, complications from splenic rupture, and anemia were achieved in 85%, 50%, 62%, and 21% of patients, respectively. Perioperative morbidity (n = 30) included infections/sepsis in 6 (20%), intraabdominal bleeding in 4 (13%), venous thromboembolism (VTE) in 3 (10%), and acute lung injury in 2 (7%) patients. The median duration of hospital stay was 6 days (1‐25), with 5 deaths occurring secondary to respiratory failure (n = 2), multiorgan dysfunction (n = 2) and hemorrhagic shock (n = 1). There was no difference in overall survival between CMML patients that underwent splenectomy, in comparison to those that did not. Unlike in myelofibrosis, portal hypertension was not an indication for splenectomy and no patients developed post‐splenectomy thrombocytosis. In conclusion, apart from being a lifesaving emergent modality in the event of splenic rupture, splenectomy has an important palliative role in patients with CMML, with significant and durable improvements in spleen related symptoms and refractory cytopenias.
MASS‐FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms
Kourelis, Taxiarchis , Murray, David , Dasari, Surendra , Kumar, Sanjay , Barnidge, David R. , Arendt, Bonnie K., Milani, Paolo , Merlini, Giampaolo , Ramı́rez-Alvarado, Marina , Kyle, Robert A. , Murray, David L., Barnidge, David, Arendt, Bonnie, Milani, Paolo , Ramirez-Alvarado, Marina, Merlini, Giampaolo , Ramirez-Alvarado, Marina , Madden, Benjamin J. , Dispenzieri, Angela , Kumar, Sanjay

Mayo Clinic

American Journal of Hematology | August 14, 2018 | Volume: 93 | Issue: 11 | Pages: No page available

10.1002/ajh.25244 | PMID 30105838 Get It

Adolescents’ and Parents’ Attitudes Toward Adolescent Clinical Trial Participation: Changes Over One Year
Tsevat, Rebecca K. , Breitkopf, Carmen Radecki , Landers, Sara E. , Roche, Ariel M. de, Mauro, Christine , Ipp, Lisa, Catallozzi, Marina , Rosenthal, Susan L. , Roche, Ariel M. de

Mayo Clinic

Journal of Empirical Research on Human Research Ethics | August 14, 2018 | Volume: 13 | Issue: 4 | Pages: 383-390

10.1177/1556264618790889 | PMID 30103655 Get It

Little is known about how adolescents’ and parents’ thoughts about participation in clinical trials change over time. In this study, adolescent (14-17 years)–parent dyads were asked about willingness to participate in a hypothetical reproductive health study. A year later, they were asked how their thoughts about the study had changed. Qualitative responses were coded and analyzed using framework analysis. Thirty-two percent of adolescents and 18% of parents reported changes in thoughts; reasons included general changes in perception, clearer understanding, new knowledge or experiences, increased maturity/age of adolescents, and changes in participants independent of the study. Adolescents and parents may benefit from learning about studies multiple times, and investigators should account for development and new experiences to optimize adolescent research enrollment.
Cardiopulmonary Function in Thoracic Wall Deformities: What Do We Really Know?
Velazco, Cristine S. , Pulivarthi, Venkata, Arsanjani, Reza , Obermeyer, Robert J., Jaroszewski, Dawn E. , Pulivarthi, Venkata Siva Krishna Kumar, Arsanjani, Reza

Mayo Clinic

European Journal of Pediatric Surgery | August 13, 2018 | Volume: 28 | Issue: 04 | Pages: 327-346

10.1055/s-0038-1668130 | PMID 30103240 Get It

AbstractPatients with pectus excavatum (PE) frequently present with complaints of exercise intolerance and cardiopulmonary symptoms. There continues to be controversy regarding the physiologic benefits of repair. The aim of this review is to summarize and discuss recent data regarding the cardiopulmonary effects of PE deformity and the evidence for improvement obtained after surgical repair including (1) a greater efficiency of breathing (chest wall mechanics), (2) improvement in pulmonary restrictive deficits, (3) an increase in cardiac chamber size and output, with improved cardiac strain and strain rate, and (4) improvement in exercise capacity.
Teaching NeuroImages: Cerebral liposuction
Gobeske, Kevin T. , Maltais, Simon, Cloft, Harry J. , Wijdicks, Eelco F. M.

Mayo Clinic

Neurology | August 13, 2018 | Volume: 91 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000005999 | PMID 30104235 Get It